Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05318391 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT05318391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05318391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Observational
Overall status
Completed
Start date
April 14, 2021
Completion date
March 30, 2022
Enrollment
324 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gene expression profiling, lymphoma, large b-cell, diffuse